Global Custom Market Research Reports Provider Company

phone

Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market

  • Published Date: 01 Jun 2018
  • Number of Pages: 125
  • Category: Pharmaceuticals
  • Country: Asia-Pacific
Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market

Summary

Psoriasis is a common, chronic inflammatory skin condition affecting around 2-3% of the worlds population. While the main cause of psoriasis remains uncertain, immunologic, genetic, and environmental factors appear to play a role. Common symptoms of psoriasis include inflammation, swelling, and patches of red, itchy, flaky skin called skin lesions.

The most common sites of involvement are the scalp, elbows and knees, followed by nails, hands, feet and trunk. It is estimated that up to 30% of people with psoriasis eventually develop psoriatic arthritis. Psoriasis is a serious skin condition that has a significant negative impact on patients quality of life, interfering in many aspects of professional and social life.

Men and women are equally likely to get it, and the onset of psoriasis can occur at any age. However, the age of onset frequency proved to be bimodal - the first before 40 years of age and the second between 50 and 60 years of age. The extent and severity of the disease varies greatly between patients and often varies within individuals over the course of time.

There are different types of psoriasis, the most common being plaque psoriasis. Around 125 million people worldwide have psoriasis, of which 80% have plaque psoriasis. The current marketed drug landscape in psoriasis includes topical agents, systemic therapies (such as acitretin, cyclosporine and methotrexate) and biologic therapies. In recent years, the discovery of new immunological factors and better understanding of psoriasis have fundamentally changed the treatment of psoriasis and created new biological drugs against specific immunological elements that cause psoriasis.

Both IL-17 and IL-23 are promising targets in the treatment of moderate to severe plaque psoriasis. The biologic drugs targeting these cytokines and their receptors have proven to be effective and safe in clinical trials and have offered greater efficacy than pre-existing biologics, making them an attractive option for use prior to other biologics.

Therefore, during the forecast period, the dominance of TNF- inhibitors (adalimumab, infliximab and etanercept) and interleukin (IL)-12/23 inhibitor ustekinumab will be challenged by the highly effective IL-17 and IL-23 inhibitor therapies. The late-stage psoriasis pipeline is composed of promising targeted therapies that have potential to achieve approval and launch during the forecast period.

These include Sun Pharmas tildrakizumab, AbbVies risankizumab, Welichem Biotechs Tapinarof, and UCBs bimekizumab and certolizumab pegol. These new drugs will supplement current market leaders and offer broader therapeutic options.

Scope

- The Asia-Pacific psoriasis market will be valued at $1,997.3m in 2024, growing from $933.1m in 2017, at a compound annual growth rate (CAGR) of 11.5%.
- What are the key factors driving the Asia-Pacific psoriasis treatment market?
- How will novel IL-23 inhibitor therapy Tremfya, which holds first-to-market advantage, contribute to growth?
- What will be the impact of the new IL-17 and IL-23 inhibitor therapies?
- How will branded therapies be affected by upcoming pipeline therapies?
- The psoriasis pipeline contains a range of molecule types and molecular targets, including those that are well established in psoriasis and novel target therapies.
- Which molecular targets appear most frequently in the pipeline?
- Is there potential for pipeline molecules to address unmet needs within the psoriasis market?
- Late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
- How have the late-stage therapies performed in clinical trials?
- Which classes of drugs are most prominent in the pipeline?
- How will the approval of risankizumab and tildrakizumab, which hold a key advantage in terms of dosing schedule over IL-23 competitor Tremfya, affect the competitive landscape?
- Various drivers and barriers will influence the market over the forecast period.
- What barriers will limit the uptake of premium-priced therapeutics in the assessed countries?
- What factors are most likely to drive the market in these countries?
- What licensing and co-development deals have occurred within this therapy area since 2007?

Reasons to buy

- Understand the current clinical and commercial landscape through a comprehensive analysis of disease symptoms, diagnostic methods, etiology, pathophysiology, epidemiology, prognosis and treatment.
- Visualize the composition of the psoriasis market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the psoriasis pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict psoriasis market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the psoriasis deals landscape by analyzing trends in licensing and co-development deals.
Publisher Name : GBI Research

1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 11
2.3 Symptoms 12
2.3.1 Skin Manifestations 12
2.3.2 Psychological Impact 12
2.4 Etiology, Co-morbidities and Risk Factors 13
2.4.1 Genetics 13
2.4.2 Psoriatic Arthritis 13
2.4.3 Mental Health Disorders 13
2.4.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 14
2.4.5 Infections 15
2.4.6 Koebner Phenomenon 15
2.4.7 Other Immune-Mediated Diseases 15
2.5 Pathophysiology 15
2.6 Diagnosis 16
2.7 Prognosis 16
2.8 Treatment and Management 16
2.8.1 Pharmacological Therapies 17
2.8.2 Non-pharmacological Therapies 18
2.8.3 Combination and Rotational Therapies 19
2.8.4 Quality of Life Assessments 19
3 Marketed Products 20
3.1 Overview 20
3.1.1 Tremfya (guselkumab) - Janssen Biotech 21
3.1.2 Cosentyx (secukinumab) - Novartis 22
3.1.3 Otezla (apremilast) - Celgene 24
3.1.4 Alzumab (Itolizumab) - Biocon 25
3.1.5 Diavobet (calcipotriene and betamethasone dipropionate) - LEO Pharma 26
3.1.6 Lumicef (brodalumab) - Kyowa Hakko Kirin 27
3.1.7 Taltz (ixekizumab) - Eli Lilly 28
3.1.8 Stelara (ustekinumab) - Janssen Biotech 29
3.1.9 Enbrel (Etanercept) - Amgen 31
3.1.10 Remicade (Infliximab) - Janssen Biotech 32
3.1.11 Humira (Adalimumab) - AbbVie 33
3.1.12 Methotrexate 34
3.1.13 Cyclosporine 35
3.1.14 Acitretin 37
3.2 Comparative Efficacy and Safety of Marketed Products 38
4 Pipeline Analysis 40
4.1 Overview 40
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 41
4.3 Pipeline by Molecular Target 42
4.4 Promising Pipeline Candidates 44
4.4.1 Tildrakizumab - Sun Pharma 44
4.4.2 Risankizumab - AbbVie 46
4.4.3 Tapinarof - Welichem Biotech 48
4.4.4 Bimekizumab - UCB 49
4.4.5 Certolizumab Pegol - UCB 51
4.5 Comparative Efficacy and Safety of Pipeline Products 53
4.6 Product Competitiveness Framework 54
5 Clinical Trial Analysis 56
5.1 Failure Rate 56
5.1.1 Overall Failure Rate 56
5.1.2 Failure Rate by Phase and Molecule Type 58
5.1.3 Failure Rate by Phase and Molecular Target 58
5.2 Clinical Trial Size 59
5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 59
5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 60
5.2.3 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 61
5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 62
5.3 Clinical Trial Duration 63
5.3.1 Clinical Trial Duration by Molecule Type 63
5.3.2 Clinical Trial Duration by Molecular Target 64
5.4 Competitive Clinical Trials Metrics Analysis 65
6 Multi-scenario Forecast 67
6.1 Geographical Markets 67
6.2 Asia-Pacific Market 67
6.3 India 70
6.3.1 Treatment Usage Patterns 70
6.3.2 Annual Cost of Therapy 71
6.3.3 Market Size 72
6.4 China 73
6.4.1 Treatment Usage Patterns 73
6.4.2 Annual Cost of Therapy 74
6.4.3 Market Size 74
6.5 Australia 75
6.5.1 Treatment Usage Patterns 75
6.5.2 Annual Cost of Therapy 76
6.5.3 Market Size 77
6.6 South Korea 78
6.6.1 Treatment Usage Patterns 78
6.6.2 Annual Cost of Therapy 79
6.6.3 Market Size 80
6.7 Japan 81
6.7.1 Treatment Usage Patterns 81
6.7.2 Annual Cost of Therapy 82
6.7.3 Market Size 82
7 Drivers and Barriers 84
7.1 Drivers 84
7.1.1 Increasing Support and Assistance from the Healthcare Systems 84
7.1.2 Rising Prevalence 84
7.1.3 Potential for Innovative Pipeline Molecules to Address Significant Unmet Need 84
7.1.4 Increasing Acceptance of Biologics and Biosimilars 84
7.2 Barriers 85
7.2.1 Use of Phototherapy and Traditional Medicines 85
7.2.2 Low Compliance and Treatment Discontinuation 85
7.2.3 Regulatory Submissions and Clinical Trial Requirement 85
7.2.4 High Prices of Therapeutics to Slow Down Market Growth 85
7.2.5 Growing Competition to Hinder Uptake of Pipeline Drugs 86
8 Deals and Strategic Consolidations 87
8.1 Licensing Deals 87
8.1.1 Deals by Region and Value 87
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 88
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 89
8.1.4 Key Licensing Deals 92
8.2 Co-development Deals 94
8.2.1 Deals by Region and Value 94
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 95
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 95
8.2.4 Key Co-development Deals 98
9 Appendix 100
9.1 All Pipeline Drugs by Stage of Development 100
9.1.1 Discovery 100
9.1.2 Preclinical 102
9.1.3 IND/CTA-filed 105
9.1.4 Phase I 106
9.1.5 Phase II 107
9.1.6 Phase III 109
9.1.7 Pre-registration 110
9.2 Market Forecasts to 2024 110
9.2.1 Asia-Pacific 110
9.2.2 India 111
9.2.3 China 111
9.2.4 Australia 111
9.2.5 South Korea 112
9.2.6 Japan 112
9.3 Bibliography 112
9.4 Abbreviations 120
9.5 Research Methodology 121
9.5.1 Secondary Research 122
9.5.2 Marketed Product Profiles 122
9.5.3 Late-Stage Pipeline Candidates 122
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 122
9.5.5 Product Competitiveness Framework 123
9.5.6 Pipeline Analysis 123
9.5.7 Forecasting Model 123
9.5.8 Deals Data Analysis 124
9.6 Contact Us 125
9.7 Disclaimer 125

List Of Tables

1.1 List of Tables
Table 1: Psoriasis Therapeutics Market, APAC, Types of Psoriasis 10
Table 2: Psoriasis Therapeutics Market, APAC, Age Distribution of Psoriasis Prevalence in South Korea 12
Table 3: Psoriasis Therapeutics Market, Global, Licensing Deals Valued Above $10m, 2007-2017 93
Table 4: Psoriasis Therapeutics Market, Global, Co-development Deals, 2007-2017 99
Table 5: Psoriasis Therapeutics Market, Global, All Pipeline Products, Discovery, 2018 100
Table 6: Psoriasis Therapeutics Market, Global, All Pipeline Products, Preclinical, 2018 102
Table 7: Psoriasis Therapeutics Market, Global, All Pipeline Products, IND/CTA-filed, 2018 105
Table 8: Psoriasis Therapeutics Market, Global, All Pipeline Products, Phase I, 2018 106
Table 9: Psoriasis Therapeutics Market, Global, All Pipeline Products, Phase II, 2018 107
Table 10: Psoriasis Therapeutics Market, Global, All Pipeline Products, Phase III, 2018 109
Table 11: Psoriasis Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2018 110
Table 12: Psoriasis Therapeutics Market, Asia-Pacific, Market Forecast, 2017-2024 110
Table 13: Psoriasis Therapeutics Market, India, Market Forecast, 2017-2024 111
Table 14: Psoriasis Therapeutics Market, China, Market Forecast, 2017-2024 111
Table 15: Psoriasis Therapeutics Market, Australia, Market Forecast, 2017-2024 111
Table 16: Psoriasis Therapeutics Market, South Korea, Market Forecast, 2017-2024 112
Table 17: Psoriasis Therapeutics Market, Japan, Market Forecast, 2017-2024 112

List Of Figures

1.2 List of Figures
Figure 1: Psoriasis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products 39
Figure 2: Pipeline for Psoriasis Therapeutics, Global, 2018 42
Figure 3: Pipeline for Psoriasis Therapeutics by Molecular Target, Global, 2018 44
Figure 4: Psoriasis Therapeutics Market, APAC, Tildrakizumab Forecast ($m), 2018-2024 46
Figure 5: Psoriasis Therapeutics Market, APAC, Risankizumab Forecast ($m), 2019-2024 48
Figure 6: Psoriasis Therapeutics Market, APAC, Bimekizumab Forecast ($m), 2022-2024 51
Figure 7: Psoriasis Therapeutics Market, APAC, Certolizumab Pegol Market ($m), 2021-2024 53
Figure 8: Psoriasis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products 54
Figure 9: Psoriasis Therapeutics Market, Competitor Matrix for Psoriasis Marketed and Pipeline Products 55
Figure 10: Psoriasis Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2007-2017 57
Figure 11: Psoriasis Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2007-2017 58
Figure 12: Psoriasis Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007-2017 59
Figure 13: Psoriasis Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007-2017 60
Figure 14: Psoriasis Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2007-2017 61
Figure 15: Psoriasis Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2007-2017 62
Figure 16: Psoriasis Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2007-2017 63
Figure 17: Psoriasis Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2007-2017 64
Figure 18: Psoriasis Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2007-2017 65
Figure 19: Psoriasis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 65
Figure 20: Psoriasis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 66
Figure 21: Psoriasis Therapeutics Market, Asia Pacific, Treatment Usage Patterns (000), 2017-2024 68
Figure 22: Psoriasis Therapeutics Market, Asia Pacific, Market Size ($m), 2017-2024 69
Figure 23: Psoriasis Therapeutics Market, India, Treatment Usage Patterns (000), 2017-2024 70
Figure 24: Psoriasis Therapeutics Market, India, Annual Cost of Therapy ($), 2017-2024 71
Figure 25: Psoriasis Therapeutics Market, India, Market Size ($m), 2017-2024 72
Figure 26: Psoriasis Therapeutics Market, China, Treatment Usage Patterns (000), 2017-2024 73
Figure 27: Psoriasis Therapeutics Market, China, Annual Cost of Therapy ($), 2017-2024 74
Figure 28: Psoriasis Therapeutics Market, China, Market Size ($m), 2017-2024 75
Figure 29: Psoriasis Therapeutics Market, Australia, Treatment Usage Patterns (000), 2017-2024 76
Figure 30: Psoriasis Therapeutics Market, Australia, Annual Cost of Therapy ($), 2017-2024 77
Figure 31: Psoriasis Therapeutics Market, Australia, Market Size ($m), 2017-2024 78
Figure 32: Psoriasis Therapeutics Market, South Korea, Treatment Usage Patterns (000), 2017-2024 79
Figure 33: Psoriasis Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017-2024 79
Figure 34: Psoriasis Therapeutics Market, South Korea, Market Size ($m), 2017-2024 80
Figure 35: Psoriasis Therapeutics Market, Japan, Treatment Usage Patterns (000), 2017-2024 81
Figure 36: Psoriasis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2017-2024 82
Figure 37: Psoriasis Therapeutics Market, Japan, Market Size ($m), 2017-2024 83
Figure 38: Psoriasis Therapeutics Market, Global, Licensing Deals by Region and Value, 2007-2017 88
Figure 39: Psoriasis Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2017 89
Figure 40: Psoriasis Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2017 90
Figure 41: Psoriasis Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2007-2017 91
Figure 42: Psoriasis Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007-2017 92
Figure 43: Psoriasis Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2007-2017 94
Figure 44: Psoriasis Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2017 95
Figure 45: Psoriasis Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2017 96
Figure 46: Psoriasis Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2007-2017 97
Figure 47: Psoriasis Therapeutics Market, Global, Co-development Deals by Molecular Target, 2007-2017 98

Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H1, 2018 GlobalDatas clinical trial report, Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H1, 2018 provides an overview of Plaque Psoriasis (Psoriasis

View Report

Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market Psoriasis is a common, chronic inflammatory skin condition affecting around

View Report

The global market size of Psoriasis Drugs is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the end

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports